首页 > 最新文献

British Journal of Pain最新文献

英文 中文
Differences in the relationship between pain and anxiety in total knee and hip arthroplasty: a longitudinal cross-lagged analysis mediated by depression and pain catastrophizing. 全膝关节和髋关节置换术中疼痛与焦虑之间关系的差异:以抑郁和疼痛灾难化为中介的纵向交叉滞后分析。
IF 1.5 Q4 CLINICAL NEUROLOGY Pub Date : 2024-12-01 Epub Date: 2024-08-17 DOI: 10.1177/20494637241273905
Ana Cristina Paredes, Patrício Costa, Márcia Costa, Patrícia Oliveira, Pedro Varanda, Armando Almeida, Patrícia R Pinto

Acute postsurgical pain (APSP) is an important risk factor for pain chronification, with reports of being more intense after total knee arthroplasty (TKA) than after total hip arthroplasty (THA). Psychological variables have been associated with differences in postsurgical pain experience. This study aimed to analyse the longitudinal reciprocal association between pain and anxiety levels in patients undergoing TKA or THA, to investigate the moderator role of the type of surgery and to explore psychological mediators in the anxiety - pain association. Patients undergoing TKA (n = 120) or THA (n = 109) were evaluated before surgery and in the acute postsurgical period (48 h postsurgery). Presurgical assessment comprised sociodemographic, pain-related and psychological variables (anxiety, depression, pain catastrophizing, self-efficacy, optimism and satisfaction with life). Postsurgical assessment focused on pain frequency, pain intensity and anxiety. Longitudinal associations were explored using cross-lagged panel models that included the indirect effect paths through possible mediators (pain catastrophizing and depression). Multigroup analyses compared TKA and THA. In the global sample, higher APSP was predicted by higher presurgical pain and worse presurgical anxiety. Multigroup analyses revealed that worse APSP was predicted by higher presurgical anxiety in patients undergoing TKA and by higher presurgical pain in patients undergoing THA. Furthermore, there was a positive significant indirect effect of pain catastrophizing, but not depressive symptoms, in the relationship between presurgical anxiety and APSP in THA. Anxiety and APSP are differently interrelated in TKA and THA. Psychological characteristics could be managed before surgery to favour better APSP control and potentially prevent pain chronification after total joint arthroplasty.

急性手术后疼痛(APSP)是疼痛慢性化的一个重要风险因素,有报道称全膝关节置换术(TKA)后的疼痛比全髋关节置换术(THA)后的疼痛更剧烈。心理变量与手术后疼痛体验的差异有关。本研究旨在分析接受全膝关节置换术(TKA)或全髋关节置换术(THA)的患者疼痛与焦虑水平之间的纵向相互关系,研究手术类型的调节作用,并探索焦虑与疼痛关系中的心理中介因素。对接受 TKA(120 人)或 THA(109 人)手术的患者进行术前和术后急性期(术后 48 小时)评估。术前评估包括社会人口学、疼痛相关和心理变量(焦虑、抑郁、疼痛灾难化、自我效能、乐观和生活满意度)。手术后评估侧重于疼痛频率、疼痛强度和焦虑。使用交叉滞后面板模型探讨了纵向关联,该模型包括通过可能的中介因素(疼痛灾难化和抑郁)产生的间接效应路径。多组分析比较了 TKA 和 THA。在全球样本中,较高的 APSP 可通过较高的术前疼痛和较差的术前焦虑来预测。多组分析显示,接受 TKA 手术的患者术前焦虑程度越高,APSP 越低;接受 THA 手术的患者术前疼痛程度越高,APSP 越低。此外,疼痛灾难化(而非抑郁症状)对 TKA 患者术前焦虑和 APSP 之间的关系有积极显著的间接影响。在TKA和THA中,焦虑和APSP的相互关系不同。在手术前对心理特征进行管理有助于更好地控制 APSP,并有可能防止全关节成形术后疼痛慢性化。
{"title":"Differences in the relationship between pain and anxiety in total knee and hip arthroplasty: a longitudinal cross-lagged analysis mediated by depression and pain catastrophizing.","authors":"Ana Cristina Paredes, Patrício Costa, Márcia Costa, Patrícia Oliveira, Pedro Varanda, Armando Almeida, Patrícia R Pinto","doi":"10.1177/20494637241273905","DOIUrl":"10.1177/20494637241273905","url":null,"abstract":"<p><p>Acute postsurgical pain (APSP) is an important risk factor for pain chronification, with reports of being more intense after total knee arthroplasty (TKA) than after total hip arthroplasty (THA). Psychological variables have been associated with differences in postsurgical pain experience. This study aimed to analyse the longitudinal reciprocal association between pain and anxiety levels in patients undergoing TKA or THA, to investigate the moderator role of the type of surgery and to explore psychological mediators in the anxiety - pain association. Patients undergoing TKA (<i>n</i> = 120) or THA (<i>n</i> = 109) were evaluated before surgery and in the acute postsurgical period (48 h postsurgery). Presurgical assessment comprised sociodemographic, pain-related and psychological variables (anxiety, depression, pain catastrophizing, self-efficacy, optimism and satisfaction with life). Postsurgical assessment focused on pain frequency, pain intensity and anxiety. Longitudinal associations were explored using cross-lagged panel models that included the indirect effect paths through possible mediators (pain catastrophizing and depression). Multigroup analyses compared TKA and THA. In the global sample, higher APSP was predicted by higher presurgical pain and worse presurgical anxiety. Multigroup analyses revealed that worse APSP was predicted by higher presurgical anxiety in patients undergoing TKA and by higher presurgical pain in patients undergoing THA. Furthermore, there was a positive significant indirect effect of pain catastrophizing, but not depressive symptoms, in the relationship between presurgical anxiety and APSP in THA. Anxiety and APSP are differently interrelated in TKA and THA. Psychological characteristics could be managed before surgery to favour better APSP control and potentially prevent pain chronification after total joint arthroplasty.</p>","PeriodicalId":46585,"journal":{"name":"British Journal of Pain","volume":" ","pages":"482-496"},"PeriodicalIF":1.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11561940/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142649243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patient safety of adjunct pre-operative intravenous S-ketamine for pain relief in third molar surgery - a randomised, placebo-controlled, double-blind trial. 第三磨牙手术术前静脉注射S-氯胺酮辅助止痛的患者安全性--随机、安慰剂对照、双盲试验。
IF 1.3 Q4 CLINICAL NEUROLOGY Pub Date : 2024-12-01 Epub Date: 2024-06-20 DOI: 10.1177/20494637241262509
Lars B Eriksson, Torsten Gordh, Rolf Karlsten, Andreas Thor, Åke Tegelberg

Purpose: To study patient safety in third molar surgery, where two different doses of S-ketamine were administered for pain relief and compared to a placebo (saline). The primary focus was capillary oxygen saturation of the blood (SpO2) and secondarily, alterations in respiratory rate, blood pressure, pulse or adverse events.

Methods: One hundred and sixty-eight subjects were included in a randomised, placebo-controlled, double-blind trial. The two subanaesthetic study drugs were low-dose S-ketamine (0.125 mg/kg) and high-dose S-ketamine (0.25 mg/kg). Every patient was sedated with midazolam prior to infusion of the investigational drug. The teeth were surgically removed according to a routine clinical procedure, under local anaesthesia.

Results: Primary end-point for the safety aspects was capillary oxygen saturation (SpO2) after administration of the investigational drug was finished. A significant difference was found between the placebo and the high-dose group at that point (p = .021), with a decrease of saturation in the high-dose group. The lowest saturation and the number of registrations of SpO2 <90% did not show any difference between groups. Oxygen supplementation was given in circa 40% of the cases with no differences between the intervention groups. No other significant differences between groups regarding saturation or respiratory rate were noted.

Conclusion: In this study, it was safe to use adjunct preoperative single-dose intravenous S-ketamine 0.25 mg/kg body weight for pain relief, in midazolam-sedated patients receiving third molar surgery. There were no serious adverse events or symptoms of overdose nor any clinically relevant effects on circulatory or respiratory parameters.

目的:研究在第三磨牙手术中使用两种不同剂量的S-氯胺酮止痛并与安慰剂(生理盐水)进行比较的患者安全性。主要重点是毛细血管血氧饱和度(SpO2),其次是呼吸频率、血压、脉搏或不良事件的变化:168 名受试者参加了随机、安慰剂对照、双盲试验。两种亚麻醉研究药物分别为低剂量 S-氯胺酮(0.125 毫克/千克)和高剂量 S-氯胺酮(0.25 毫克/千克)。在输注研究药物之前,每位患者都使用了咪达唑仑镇静剂。按照常规临床程序,在局部麻醉下进行拔牙手术:安全方面的主要终点是给药结束后的毛细血管血氧饱和度(SpO2)。安慰剂组和大剂量组在这一点上存在明显差异(p = 021),大剂量组的饱和度有所下降。SpO2的最低饱和度和登记次数 结论:在这项研究中,对于接受第三磨牙手术的咪达唑仑镇静患者,术前单剂量静脉注射 S-Ketamine 0.25 mg/kg 体重辅助镇痛是安全的。没有出现严重不良事件或过量症状,也没有对循环或呼吸参数产生任何临床相关影响。
{"title":"Patient safety of adjunct pre-operative intravenous S-ketamine for pain relief in third molar surgery - a randomised, placebo-controlled, double-blind trial.","authors":"Lars B Eriksson, Torsten Gordh, Rolf Karlsten, Andreas Thor, Åke Tegelberg","doi":"10.1177/20494637241262509","DOIUrl":"10.1177/20494637241262509","url":null,"abstract":"<p><strong>Purpose: </strong>To study patient safety in third molar surgery, where two different doses of S-ketamine were administered for pain relief and compared to a placebo (saline). The primary focus was capillary oxygen saturation of the blood (SpO<sub>2</sub>) and secondarily, alterations in respiratory rate, blood pressure, pulse or adverse events.</p><p><strong>Methods: </strong>One hundred and sixty-eight subjects were included in a randomised, placebo-controlled, double-blind trial. The two subanaesthetic study drugs were low-dose S-ketamine (0.125 mg/kg) and high-dose S-ketamine (0.25 mg/kg). Every patient was sedated with midazolam prior to infusion of the investigational drug. The teeth were surgically removed according to a routine clinical procedure, under local anaesthesia.</p><p><strong>Results: </strong>Primary end-point for the safety aspects was capillary oxygen saturation (SpO<sub>2</sub>) after administration of the investigational drug was finished. A significant difference was found between the placebo and the high-dose group at that point (<i>p</i> = .021), with a decrease of saturation in the high-dose group. The lowest saturation and the number of registrations of SpO<sub>2</sub> <90% did not show any difference between groups. Oxygen supplementation was given in circa 40% of the cases with no differences between the intervention groups. No other significant differences between groups regarding saturation or respiratory rate were noted.</p><p><strong>Conclusion: </strong>In this study, it was safe to use adjunct preoperative single-dose intravenous S-ketamine 0.25 mg/kg body weight for pain relief, in midazolam-sedated patients receiving third molar surgery. There were no serious adverse events or symptoms of overdose nor any clinically relevant effects on circulatory or respiratory parameters.</p>","PeriodicalId":46585,"journal":{"name":"British Journal of Pain","volume":" ","pages":"450-460"},"PeriodicalIF":1.3,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11561931/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142649249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Persistent post-discharge opioid use and opioid stewardship: A single-centre retrospective cohort study. 出院后阿片类药物的持续使用与阿片类药物管理:单中心回顾性队列研究。
IF 1.5 Q4 CLINICAL NEUROLOGY Pub Date : 2024-12-01 Epub Date: 2024-08-20 DOI: 10.1177/20494637241276106
Sandra Hapca, Louise Peet, Christine Gibson, Andrea Harvey, Patrice Forget

Persistent post-operative opioid use is a public health concern contributing to population morbidity and mortality. Opioid stewardship is a strategy adopted to rationalise opioid prescribing and limit harmful use. We describe persistent post-discharge opioid use rates and risk factors in a single-centre cohort and describe the opioid stewardship role of our Acute Pain Service (APS). We conducted a retrospective 4-year cohort study of inpatients referred to the APS and discharged with new strong opioids prescribed. We investigated persistent post-discharge opioid use rates, risk factors and patterns of opioid use after community follow-up by APS. We found that 24% of patients discharged with new strong opioids developed persistent opioid use. Risk factors associated with persistent post-discharge opioid use in our cohort included female sex (Odds Ratios [95% confidence interval], p value, OR: 1.89 [1.11-3.22], p = 0.019), pre-admission mental health history (OR: 2.85 [1.64-4.95], p < 0.001) and pre-admission opioid use (OR: 1.79 [1.03-3.11], p = 0.004). A smaller proportion of patients with APS follow-up in community developed persistent opioid use (22%) compared to those without (32%). We conclude that having opioids prescribed at time of discharge can result in persistent opioid use in up to a quarter of patients. The APS has an important protective role in rationalising opioid use in hospital but also following discharge. Development of further opioid stewardship policies is needed including improvement of patient and staff awareness and pre-operative assessment of patients with recognised risk factors.

术后持续使用阿片类药物是一个公共卫生问题,会导致人群发病和死亡。阿片类药物管理是一种旨在合理开具阿片类药物处方并限制有害使用的策略。我们描述了单中心队列中出院后阿片类药物的持续使用率和风险因素,并介绍了我们的急性疼痛服务(APS)在阿片类药物管理中的作用。我们对转诊至 APS 并开具了新的强效阿片类药物处方的出院住院患者进行了一项为期 4 年的回顾性队列研究。我们调查了出院后阿片类药物的持续使用率、风险因素以及 APS 社区随访后阿片类药物的使用模式。我们发现,24% 的患者在出院时使用了新的强效阿片类药物,并形成了持续使用阿片类药物的现象。在我们的队列中,与出院后持续使用阿片类药物相关的风险因素包括女性(Odds Ratios [95% confidence interval], p value, OR: 1.89 [1.11-3.22], p = 0.019)、入院前精神健康史(OR: 2.85 [1.64-4.95], p < 0.001)和入院前阿片类药物使用(OR: 1.79 [1.03-3.11], p = 0.004)。在社区接受 APS 随访的患者中,持续使用阿片类药物的比例(22%)低于未接受随访的患者(32%)。我们的结论是,出院时开具阿片类药物处方会导致多达四分之一的患者持续使用阿片类药物。阿片类药物管理计划(APS)在合理使用住院阿片类药物以及出院后阿片类药物使用方面发挥着重要的保护作用。需要进一步制定阿片类药物管理政策,包括提高患者和医务人员的认识,以及对具有公认风险因素的患者进行术前评估。
{"title":"Persistent post-discharge opioid use and opioid stewardship: A single-centre retrospective cohort study.","authors":"Sandra Hapca, Louise Peet, Christine Gibson, Andrea Harvey, Patrice Forget","doi":"10.1177/20494637241276106","DOIUrl":"10.1177/20494637241276106","url":null,"abstract":"<p><p>Persistent post-operative opioid use is a public health concern contributing to population morbidity and mortality. Opioid stewardship is a strategy adopted to rationalise opioid prescribing and limit harmful use. We describe persistent post-discharge opioid use rates and risk factors in a single-centre cohort and describe the opioid stewardship role of our Acute Pain Service (APS). We conducted a retrospective 4-year cohort study of inpatients referred to the APS and discharged with new strong opioids prescribed. We investigated persistent post-discharge opioid use rates, risk factors and patterns of opioid use after community follow-up by APS. We found that 24% of patients discharged with new strong opioids developed persistent opioid use. Risk factors associated with persistent post-discharge opioid use in our cohort included female sex (Odds Ratios [95% confidence interval], <i>p</i> value, OR: 1.89 [1.11-3.22], <i>p</i> = 0.019), pre-admission mental health history (OR: 2.85 [1.64-4.95], <i>p</i> < 0.001) and pre-admission opioid use (OR: 1.79 [1.03-3.11], <i>p</i> = 0.004). A smaller proportion of patients with APS follow-up in community developed persistent opioid use (22%) compared to those without (32%). We conclude that having opioids prescribed at time of discharge can result in persistent opioid use in up to a quarter of patients. The APS has an important protective role in rationalising opioid use in hospital but also following discharge. Development of further opioid stewardship policies is needed including improvement of patient and staff awareness and pre-operative assessment of patients with recognised risk factors.</p>","PeriodicalId":46585,"journal":{"name":"British Journal of Pain","volume":" ","pages":"497-503"},"PeriodicalIF":1.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11561955/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142649185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effectiveness of a novel multicomponent treatment in women with fibromyalgia: A randomized clinical trial. 新型多成分疗法对纤维肌痛女性患者的疗效:随机临床试验。
IF 1.5 Q4 CLINICAL NEUROLOGY Pub Date : 2024-12-01 Epub Date: 2024-10-18 DOI: 10.1177/20494637241293760
Felipe Araya-Quintanilla, Celia Álvarez-Bueno, Iván Cavero-Redondo, Robinson Ramírez-Vélez, Walter Sepúlveda-Loyola, Héctor Gutiérrez-Espinoza

Background: Multicomponent treatment is commonly used. However, there are no studies that included graded motor imagery and therapeutic neuroscience education to multicomponent treatment for patients with fibromyalgia This study aims to compare the short-term effects (at 12 weeks) of a multicomponent treatment combined with graded motor imagery and therapeutic neuroscience education versus standard treatment in patients with FM.

Methods: The study was a single-blinded randomized controlled trial. Sixty-five women with a clinical diagnosis of FM were randomly allocated (1:1) into two groups. The experimental group (n = 33) received a novel multicomponent treatment combined with graded motor imagery and neuroscience education. The control group (n = 32) received a standard treatment including pharmacotherapy and standard physician education. The primary outcome was pain intensity assessed with the Numeric Pain Rating Scale (NPRS). The secondary outcomes were changes in the Fibromyalgia Impact Questionnaire (FIQ), the Pain Catastrophizing Scale (PCS), the Tampa Scale of Kinesiophobia (TSK-17), and the Pittsburgh Sleep Quality Index (PSQI) scores. All outcomes were assessed at baseline and 12 weeks.

Results: All of the participants completed the trial. The between-group mean differences at 12 weeks were: NPRS-1.18 points (95% confidence interval [CI] -0.4 to -1.8; η2 = 0.47; p < .001); FIQ-16.21 points (95% CI -10.9 to -22.1; η2 = 0.58; p < .001); PCS total domain -12.5 points (95% CI -7.2 to -17.8; η2 = 0.61; p < .001); TSK-17-6.15 points (95% CI -3.5 to -8.7; η2 = 0.52; p < .001); and PSQI-2.74 points (95% CI -1.4 to 4.0; η2 = 0.54; p < .001). All differences were statistically significant in favor of the novel multicomponent treatment group and had a large effect size.

Conclusions: In the short term, a novel multicomponent treatment, including graded motor imagery and neuroscience education, was an effective therapeutic intervention for improving clinical outcomes compared with standard treatment in women with FM. Additional studies are needed to support long-term clinical effectiveness in these patients.

背景:多成分治疗是常用的治疗方法。本研究旨在比较结合分级运动想象和治疗性神经科学教育的多组分疗法与标准疗法对纤维肌痛患者的短期疗效(12 周):该研究是一项单盲随机对照试验。65名临床诊断为FM的妇女被随机分配(1:1)到两组。实验组(n = 33)接受新颖的多成分治疗,并结合分级运动想象和神经科学教育。对照组(n = 32)接受标准治疗,包括药物治疗和标准医生教育。主要研究结果是用数字疼痛评分量表(NPRS)评估疼痛强度。次要结果是纤维肌痛影响问卷 (FIQ)、疼痛灾难化量表 (PCS)、坦帕运动恐惧量表 (TSK-17) 和匹兹堡睡眠质量指数 (PSQI) 评分的变化。所有结果均在基线和 12 周时进行评估:所有参与者都完成了试验。12 周时的组间平均差异为NPRS-1.18分(95% 置信区间 [CI] -0.4至-1.8;η2 = 0.47;p < .001);FIQ-16.21分(95% CI -10.9至-22.1;η2 = 0.58;p < .001);PCS总域-12.5分 (95% CI -7.2 to -17.8; η2 = 0.61; p < .001);TSK-17-6.15分 (95% CI -3.5 to -8.7; η2 = 0.52; p < .001);PSQI-2.74分 (95% CI -1.4 to 4.0; η2 = 0.54; p < .001)。所有差异在统计学上都对新型多组分治疗组有显著影响,且影响程度大:结论:在短期内,与标准治疗相比,包括分级运动想象和神经科学教育在内的新型多成分治疗是一种有效的治疗干预措施,可改善女性 FM 患者的临床疗效。还需要更多的研究来支持这些患者的长期临床疗效。
{"title":"Effectiveness of a novel multicomponent treatment in women with fibromyalgia: A randomized clinical trial.","authors":"Felipe Araya-Quintanilla, Celia Álvarez-Bueno, Iván Cavero-Redondo, Robinson Ramírez-Vélez, Walter Sepúlveda-Loyola, Héctor Gutiérrez-Espinoza","doi":"10.1177/20494637241293760","DOIUrl":"10.1177/20494637241293760","url":null,"abstract":"<p><strong>Background: </strong>Multicomponent treatment is commonly used. However, there are no studies that included graded motor imagery and therapeutic neuroscience education to multicomponent treatment for patients with fibromyalgia This study aims to compare the short-term effects (at 12 weeks) of a multicomponent treatment combined with graded motor imagery and therapeutic neuroscience education versus standard treatment in patients with FM.</p><p><strong>Methods: </strong>The study was a single-blinded randomized controlled trial. Sixty-five women with a clinical diagnosis of FM were randomly allocated (1:1) into two groups. The experimental group (<i>n</i> = 33) received a novel multicomponent treatment combined with graded motor imagery and neuroscience education. The control group (<i>n</i> = 32) received a standard treatment including pharmacotherapy and standard physician education. The primary outcome was pain intensity assessed with the Numeric Pain Rating Scale (NPRS). The secondary outcomes were changes in the Fibromyalgia Impact Questionnaire (FIQ), the Pain Catastrophizing Scale (PCS), the Tampa Scale of Kinesiophobia (TSK-17), and the Pittsburgh Sleep Quality Index (PSQI) scores. All outcomes were assessed at baseline and 12 weeks.</p><p><strong>Results: </strong>All of the participants completed the trial. The between-group mean differences at 12 weeks were: NPRS-1.18 points (95% confidence interval [CI] -0.4 to -1.8; η<sup>2</sup> = 0.47; <i>p</i> < .001); FIQ-16.21 points (95% CI -10.9 to -22.1; η<sup>2</sup> = 0.58; <i>p</i> < .001); PCS total domain -12.5 points (95% CI -7.2 to -17.8; η<sup>2</sup> = 0.61; <i>p</i> < .001); TSK-17-6.15 points (95% CI -3.5 to -8.7; η<sup>2</sup> = 0.52; <i>p</i> < .001); and PSQI-2.74 points (95% CI -1.4 to 4.0; η<sup>2</sup> = 0.54; <i>p</i> < .001). All differences were statistically significant in favor of the novel multicomponent treatment group and had a large effect size.</p><p><strong>Conclusions: </strong>In the short term, a novel multicomponent treatment, including graded motor imagery and neuroscience education, was an effective therapeutic intervention for improving clinical outcomes compared with standard treatment in women with FM. Additional studies are needed to support long-term clinical effectiveness in these patients.</p>","PeriodicalId":46585,"journal":{"name":"British Journal of Pain","volume":" ","pages":"504-513"},"PeriodicalIF":1.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11559512/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142629803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The value of social relationships in the biopsychosocial model of pain. 疼痛的生物心理社会模式中社会关系的价值。
IF 1.5 Q4 CLINICAL NEUROLOGY Pub Date : 2024-12-01 Epub Date: 2024-10-23 DOI: 10.1177/20494637241297274
Daniela Ghio, Sarah Peters
{"title":"The value of social relationships in the biopsychosocial model of pain.","authors":"Daniela Ghio, Sarah Peters","doi":"10.1177/20494637241297274","DOIUrl":"10.1177/20494637241297274","url":null,"abstract":"","PeriodicalId":46585,"journal":{"name":"British Journal of Pain","volume":" ","pages":"448-449"},"PeriodicalIF":1.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11559515/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142629837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Do threats and reassurances reside in the biological, psychological or social domain? A qualitative study in adults and young people with chronic pain. 威胁和保证属于生物、心理还是社会领域?一项针对患有慢性疼痛的成年人和年轻人的定性研究。
IF 1.3 Q4 CLINICAL NEUROLOGY Pub Date : 2024-12-01 Epub Date: 2024-06-24 DOI: 10.1177/20494637241263291
Hannah Kennedy, Daniel S Harvie, Michel W Coppieters

Objective: Understanding biopsychosocial contributions to a sensitised pain system is a key target of many pain management programs. The 'Protectometer' is a freely available educational tool that guides people with chronic pain to explore their personal threats and reassurances, identifying them as 'DIMs' (danger in me) or 'SIMs' (safety in me), to guide personalised pain management. This study aimed to explore common types of DIMs and SIMs, and examine differences between adults and young people.

Materials and methods: A retrospective qualitative study was conducted. Written DIMs (n = 504) and SIMs (n = 711) were collected from 96 participants with chronic pain (77 adults aged 18-85 years; 19 young people aged 9-17 years) across 15 multidisciplinary pain management groups. DIMs and SIMs were transcribed and analysed using deductive content analysis.

Results: Four overarching themes were identified: 'Engaging with the environment', 'In my body', 'My emotional health', and 'Activities and behaviours'. Similarities in SIMs were found, with the greatest proportion of SIMs in the social domain (49% adults; 47% young people). While adult DIMs were fairly evenly spread across the biological (37%), psychological (27%) and social domains (36%), young people's DIMs were predominantly in the psychological (44%) and social (43%) domains.

Discussion: These findings provide insights into common threats and reassurances people in pain perceive, and revealed age-related differences in biopsychosocial contributions to pain and pain relief. Findings also highlight the importance of social-based interventions as part of pain management therapies for both adults and young people.

目的:了解生物心理社会因素对敏感疼痛系统的影响是许多疼痛管理计划的主要目标。保护计 "是一种免费提供的教育工具,可引导慢性疼痛患者探索他们的个人威胁和保证,将其识别为 "DIMs"(我的危险)或 "SIMs"(我的安全),以指导个性化疼痛管理。本研究旨在探索常见的 "DIMs "和 "SIMs "类型,并研究成年人和年轻人之间的差异:进行了一项回顾性定性研究。从 15 个多学科疼痛管理小组的 96 名慢性疼痛参与者(77 名 18-85 岁的成年人;19 名 9-17 岁的年轻人)中收集了书面的 DIMs(n = 504)和 SIMs(n = 711)。对 DIMs 和 SIMs 进行了转录,并采用演绎内容分析法进行了分析:结果:确定了四个总体主题:结果:确定了四个总体主题:"参与环境"、"我的身体"、"我的情绪健康 "以及 "活动和行为"。研究发现,SIMs 具有相似性,其中社会领域的 SIMs 所占比例最大(49% 的成年人;47% 的年轻人)。成年人的情感困惑在生物(37%)、心理(27%)和社会(36%)领域的分布相当均匀,而年轻人的情感困惑则主要集中在心理(44%)和社会(43%)领域:讨论:这些研究结果提供了有关疼痛患者所感知的常见威胁和保证的见解,并揭示了与年龄有关的生物心理社会对疼痛和疼痛缓解的贡献差异。研究结果还强调了以社会为基础的干预措施作为成人和年轻人疼痛管理疗法一部分的重要性。
{"title":"Do threats and reassurances reside in the biological, psychological or social domain? A qualitative study in adults and young people with chronic pain.","authors":"Hannah Kennedy, Daniel S Harvie, Michel W Coppieters","doi":"10.1177/20494637241263291","DOIUrl":"10.1177/20494637241263291","url":null,"abstract":"<p><strong>Objective: </strong>Understanding biopsychosocial contributions to a sensitised pain system is a key target of many pain management programs. The 'Protectometer' is a freely available educational tool that guides people with chronic pain to explore their personal threats and reassurances, identifying them as 'DIMs' (danger in me) or 'SIMs' (safety in me), to guide personalised pain management. This study aimed to explore common types of DIMs and SIMs, and examine differences between adults and young people.</p><p><strong>Materials and methods: </strong>A retrospective qualitative study was conducted. Written DIMs (<i>n</i> = 504) and SIMs (<i>n</i> = 711) were collected from 96 participants with chronic pain (77 adults aged 18-85 years; 19 young people aged 9-17 years) across 15 multidisciplinary pain management groups. DIMs and SIMs were transcribed and analysed using deductive content analysis.</p><p><strong>Results: </strong>Four overarching themes were identified: 'Engaging with the environment', 'In my body', 'My emotional health', and 'Activities and behaviours'. Similarities in SIMs were found, with the greatest proportion of SIMs in the social domain (49% adults; 47% young people). While adult DIMs were fairly evenly spread across the biological (37%), psychological (27%) and social domains (36%), young people's DIMs were predominantly in the psychological (44%) and social (43%) domains.</p><p><strong>Discussion: </strong>These findings provide insights into common threats and reassurances people in pain perceive, and revealed age-related differences in biopsychosocial contributions to pain and pain relief. Findings also highlight the importance of social-based interventions as part of pain management therapies for both adults and young people.</p>","PeriodicalId":46585,"journal":{"name":"British Journal of Pain","volume":" ","pages":"472-481"},"PeriodicalIF":1.3,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11561933/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142649245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Botulinum toxin: Should we reconsider its place in the treatment of neuropathic pain? 肉毒杆菌毒素:我们是否应该重新考虑它在神经病理性疼痛治疗中的地位?
IF 1.5 Q4 CLINICAL NEUROLOGY Pub Date : 2024-10-01 Epub Date: 2024-09-11 DOI: 10.1177/20494637241282323
Paul Bhalla
{"title":"Botulinum toxin: Should we reconsider its place in the treatment of neuropathic pain?","authors":"Paul Bhalla","doi":"10.1177/20494637241282323","DOIUrl":"10.1177/20494637241282323","url":null,"abstract":"","PeriodicalId":46585,"journal":{"name":"British Journal of Pain","volume":"18 5","pages":"386-387"},"PeriodicalIF":1.5,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11451518/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142381974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
What influences post-operative opioid requirements for tibial fractures? 是什么影响了胫骨骨折术后对阿片类药物的需求?
IF 1.5 Q4 CLINICAL NEUROLOGY Pub Date : 2024-10-01 Epub Date: 2024-06-18 DOI: 10.1177/20494637241261013
James Zhang, Aaron Limonard, Florence Bradshaw, Ishrat Hussain, Maša Josipović, Matija Krkovic

Introduction: Currently there are few opioid prescribing guidelines for orthopaedic fractures. Long-term post-surgical analgesia requirements, understandably, vary between orthopaedic cases. Our study aims to provide detailed information to clinicians and policy makers, on the opioid requirement associations for patients sustaining tibial fractures.

Methods: This study reviewed all patients sustaining an isolated tibial fracture at a major trauma centre that were operated on within 1 month of injury, from 2015 to 2022. The total opioid dosage used each month in morphine milligrams equivalents (MME) and the number of days opioids were used each month, within the first-year post-surgery were collected, representing the strength and coverage of opioid analgesia in the post-operative stage, respectively. We compared opioid strength and coverage requirements with types of definitive fracture fixations, location, fracture type and concurrent patient medical comorbidities to assess for any trends.

Results: A total of 1814 patients sustaining a combined of 1970 fractures were included in the study. Tibial plateau fractures had the highest opioid strength and coverage requirements in each month and the entire year (p < .05). Across all fracture locations, Ex Fix frame showed higher opioid strength and coverage requirements compared to both IM nailing and plate ORIF. With regard to opioid coverage in the presence of specific comorbidities, only chronic kidney disease (quotient: 1.37, 95% Confidence interval [95%CI] = 1.19-1.55, p = .002) and hypertension (quotient: 1.34, 95%CI = 1.14-1.53, p = .009) showed significance at the 1-year overall level. For opioid strength, Chronic Kidney Disease (quotient: 1.72, 95%CI = 1.41-2.03 p = .005) and COPD (quotient: 1.90, 95%CI = 1.44-2.36, p = .014), show significance at the 1-year overall level.

Conclusion: Our study details opioid requirements post-surgery amongst tibial fractures with subgroup analysis assessing opioid needs amongst specific fracture locations, types, surgical techniques and medical comorbidities. This framework aids clinicians in anticipating rehabilitation and assists in risk stratifying patients at injury onset.

导言:目前,几乎没有针对骨科骨折的阿片类药物处方指南。可以理解的是,不同骨科病例的术后长期镇痛需求各不相同。我们的研究旨在为临床医生和政策制定者提供有关胫骨骨折患者阿片类药物需求关联的详细信息:本研究回顾了 2015 年至 2022 年期间在一家大型创伤中心接受手术的所有在受伤后 1 个月内发生孤立性胫骨骨折的患者。收集了术后第一年内每月阿片类药物的总用量(吗啡毫克当量)和每月使用阿片类药物的天数,分别代表术后阶段阿片类药物镇痛的强度和覆盖范围。我们将阿片类药物的使用强度和覆盖范围要求与最终骨折固定的类型、位置、骨折类型和患者的并发症进行了比较,以评估任何趋势:研究共纳入了1814名骨折患者,总计1970例。胫骨平台骨折患者每月和全年的阿片类药物剂量和覆盖范围需求最高(p < .05)。在所有骨折部位,Ex Fix固定架与IM钉和钢板ORIF相比,都显示出更高的阿片类药物强度和覆盖需求。关于存在特定合并症时的阿片类药物覆盖率,只有慢性肾病(商数:1.37,95% 置信区间 [95%CI] = 1.19-1.55,p = .002)和高血压(商数:1.34,95%CI = 1.14-1.53,p = .009)在 1 年总体水平上显示出显著性。慢性肾脏病(商数:1.72,95%CI = 1.41-2.03,p = .005)和慢性阻塞性肺病(商数:1.90,95%CI = 1.44-2.36,p = .014)的阿片类药物强度在 1 年总体水平上显示出显著性:我们的研究详细介绍了胫骨骨折患者手术后对阿片类药物的需求,并通过亚组分析评估了特定骨折部位、类型、手术技术和合并症对阿片类药物的需求。这一框架有助于临床医生预测康复情况,并在患者受伤初期对其进行风险分层。
{"title":"What influences post-operative opioid requirements for tibial fractures?","authors":"James Zhang, Aaron Limonard, Florence Bradshaw, Ishrat Hussain, Maša Josipović, Matija Krkovic","doi":"10.1177/20494637241261013","DOIUrl":"10.1177/20494637241261013","url":null,"abstract":"<p><strong>Introduction: </strong>Currently there are few opioid prescribing guidelines for orthopaedic fractures. Long-term post-surgical analgesia requirements, understandably, vary between orthopaedic cases. Our study aims to provide detailed information to clinicians and policy makers, on the opioid requirement associations for patients sustaining tibial fractures.</p><p><strong>Methods: </strong>This study reviewed all patients sustaining an isolated tibial fracture at a major trauma centre that were operated on within 1 month of injury, from 2015 to 2022. The total opioid dosage used each month in morphine milligrams equivalents (MME) and the number of days opioids were used each month, within the first-year post-surgery were collected, representing the strength and coverage of opioid analgesia in the post-operative stage, respectively. We compared opioid strength and coverage requirements with types of definitive fracture fixations, location, fracture type and concurrent patient medical comorbidities to assess for any trends.</p><p><strong>Results: </strong>A total of 1814 patients sustaining a combined of 1970 fractures were included in the study. Tibial plateau fractures had the highest opioid strength and coverage requirements in each month and the entire year (<i>p</i> < .05). Across all fracture locations, Ex Fix frame showed higher opioid strength and coverage requirements compared to both IM nailing and plate ORIF. With regard to opioid coverage in the presence of specific comorbidities, only chronic kidney disease (quotient: 1.37, 95% Confidence interval [95%CI] = 1.19-1.55, <i>p</i> = .002) and hypertension (quotient: 1.34, 95%CI = 1.14-1.53, <i>p</i> = .009) showed significance at the 1-year overall level. For opioid strength, Chronic Kidney Disease (quotient: 1.72, 95%CI = 1.41-2.03 <i>p</i> = .005) and COPD (quotient: 1.90, 95%CI = 1.44-2.36, <i>p</i> = .014), show significance at the 1-year overall level.</p><p><strong>Conclusion: </strong>Our study details opioid requirements post-surgery amongst tibial fractures with subgroup analysis assessing opioid needs amongst specific fracture locations, types, surgical techniques and medical comorbidities. This framework aids clinicians in anticipating rehabilitation and assists in risk stratifying patients at injury onset.</p>","PeriodicalId":46585,"journal":{"name":"British Journal of Pain","volume":"18 5","pages":"433-443"},"PeriodicalIF":1.5,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11440535/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142362209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Intrathecal drug delivery for the management of pain and spasticity in adults: British Pain Society's recommendations for best clinical practice. 鞘内给药治疗成人疼痛和痉挛:英国疼痛学会最佳临床实践建议。
IF 1.3 Q4 CLINICAL NEUROLOGY Pub Date : 2024-09-07 DOI: 10.1177/20494637241280356
Sam Eldabe, Rui Duarte, Simon Thomson, Stana Bojanic, Paul Farquhar-Smith, Somnath Bagchi, Lis Farquhar, Bill Wetherill, Sue Copley

The British Pain Society updated their recommendations on intrathecal drug delivery (ITDD) for the management of pain and spasticity in adults. The recommendations are primarily evidence based but where necessary comprise the consensus opinion of the working group. The recommendations are accompanied by information for patients and their carers, intended to inform and support patients in their decision making. The updated guidance includes recent evidence base of ITDD use in pain and spasticity, address the issues of drug pump compatibility following the latest manufacturer and Medicines and Healthcare products Regulatory Agency (MHRA) recommendations as well as provide an update on the indications and complication management particularly endocrine complications and intrathecal granuloma formation.

英国疼痛学会更新了关于鞘内给药 (ITDD) 治疗成人疼痛和痉挛的建议。这些建议主要以证据为基础,但在必要时也包含了工作组的一致意见。这些建议附有为患者及其护理者提供的信息,旨在为患者的决策提供信息和支持。更新后的指南包括 ITDD 用于疼痛和痉挛的最新证据基础,根据制造商和药品与保健品监管局 (MHRA) 的最新建议解决了药泵兼容性问题,并提供了适应症和并发症管理方面的最新信息,尤其是内分泌并发症和鞘内肉芽肿的形成。
{"title":"Intrathecal drug delivery for the management of pain and spasticity in adults: British Pain Society's recommendations for best clinical practice.","authors":"Sam Eldabe, Rui Duarte, Simon Thomson, Stana Bojanic, Paul Farquhar-Smith, Somnath Bagchi, Lis Farquhar, Bill Wetherill, Sue Copley","doi":"10.1177/20494637241280356","DOIUrl":"10.1177/20494637241280356","url":null,"abstract":"<p><p>The British Pain Society updated their recommendations on intrathecal drug delivery (ITDD) for the management of pain and spasticity in adults. The recommendations are primarily evidence based but where necessary comprise the consensus opinion of the working group. The recommendations are accompanied by information for patients and their carers, intended to inform and support patients in their decision making. The updated guidance includes recent evidence base of ITDD use in pain and spasticity, address the issues of drug pump compatibility following the latest manufacturer and Medicines and Healthcare products Regulatory Agency (MHRA) recommendations as well as provide an update on the indications and complication management particularly endocrine complications and intrathecal granuloma formation.</p>","PeriodicalId":46585,"journal":{"name":"British Journal of Pain","volume":" ","pages":"20494637241280356"},"PeriodicalIF":1.3,"publicationDate":"2024-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11561936/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142649247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prehabilitation: The underutilised weapon for chronic pain management. 预康复:未被充分利用的慢性疼痛治疗武器。
IF 1.3 Q4 CLINICAL NEUROLOGY Pub Date : 2024-08-01 Epub Date: 2024-04-29 DOI: 10.1177/20494637241250239
Lydia V Tidmarsh, Richard Harrison, Katherine A Finlay

Objective: Prehabilitation encompasses preparatory clinical intervention(s) delivered during the period between diagnosis and treatment commencement. Despite widespread successful usage preoperatively, psychological prehabilitation is neglected in outpatient chronic pain management. Although pain management waitlists are associated with treatment attrition and psychological and physical decline, this time window is underutilised in preventing escalation. Waitlists present an under-explored opportunity to 'prehabilitate' patients waiting for treatment. This topical review aimed to: (1) examine the effectiveness of psychological prehabilitation for pain services; (2) evaluate the psychological and physical decline associated with waiting for pain management; (3) highlight key psychological prehabilitative targets for increasing treatment engagement; (4) promote pain management psychological prehabilitation within personalised pain medicine, building recommendations for future interventions.

Methods: Studies regarding the impact of waitlists and prehabilitation for chronic pain were reviewed.

Results: Findings demonstrated that the psychological constructs of patient expectations, health locus of control, self-efficacy and pain catastrophizing dynamically influence attrition, treatment engagement and outcomes while waiting. These constructs are amenable to change, emphasising their potential utility within a targeted waitlist intervention.

Conclusions: Prehabilitating chronic pain patients towards treatment engagement could circumvent cycles of failed treatment seeking, preventing psychological and physical decline, and reducing healthcare utilisation. Utilising the waitlist to identify psychosocial risk factors (external health locus of control, low self-efficacy and high pain catastrophizing) would identify who requires additional support to prevent increased risk of treatment failure, enhancing personalised care before prescribed treatment is accessed. This review cements the urgent need for pain services to engage proactively with prehabilitation innovation.

目的:术前康复包括从诊断到开始治疗期间的准备性临床干预。尽管术前心理康复治疗被广泛应用,但在门诊慢性疼痛治疗中却被忽视。尽管疼痛治疗等待名单与治疗流失、心理和生理衰退有关,但这一时间窗口在防止治疗升级方面却未得到充分利用。候诊名单为等待治疗的患者提供了 "预康复 "的机会。本专题综述旨在(1)研究疼痛服务心理康复的有效性;(2)评估与等待疼痛治疗相关的心理和生理衰退;(3)强调提高治疗参与度的关键心理康复目标;(4)在个性化疼痛医学中促进疼痛治疗心理康复,为未来的干预措施提供建议:方法:回顾了有关慢性疼痛等待名单和预康复的影响的研究:研究结果表明,患者期望、健康控制点、自我效能感和疼痛灾难化等心理结构动态地影响着等待期间的流失、治疗参与度和治疗结果。这些心理结构易于改变,强调了它们在有针对性的候诊干预中的潜在作用:对慢性疼痛患者进行参与治疗前的康复训练,可以避免寻求治疗失败的循环,防止心理和生理衰退,减少医疗保健的使用。利用候诊清单来识别心理社会风险因素(外部健康控制定位、低自我效能感和高疼痛灾难化),可以确定哪些患者需要额外支持以防止治疗失败风险的增加,从而在接受处方治疗前加强个性化护理。本综述强调了疼痛服务部门主动参与康复前创新的迫切需要。
{"title":"Prehabilitation: The underutilised weapon for chronic pain management.","authors":"Lydia V Tidmarsh, Richard Harrison, Katherine A Finlay","doi":"10.1177/20494637241250239","DOIUrl":"10.1177/20494637241250239","url":null,"abstract":"<p><strong>Objective: </strong>Prehabilitation encompasses preparatory clinical intervention(s) delivered during the period between diagnosis and treatment commencement. Despite widespread successful usage preoperatively, <i>psychological</i> prehabilitation is neglected in outpatient chronic pain management. Although pain management waitlists are associated with treatment attrition and psychological and physical decline, this time window is underutilised in preventing escalation. Waitlists present an under-explored opportunity to 'prehabilitate' patients waiting for treatment. This topical review aimed to: (1) examine the effectiveness of psychological prehabilitation for pain services; (2) evaluate the psychological and physical decline associated with waiting for pain management; (3) highlight key psychological prehabilitative targets for increasing treatment engagement; (4) promote pain management psychological prehabilitation within personalised pain medicine, building recommendations for future interventions.</p><p><strong>Methods: </strong>Studies regarding the impact of waitlists and prehabilitation for chronic pain were reviewed.</p><p><strong>Results: </strong>Findings demonstrated that the psychological constructs of patient expectations, health locus of control, self-efficacy and pain catastrophizing dynamically influence attrition, treatment engagement and outcomes while waiting. These constructs are amenable to change, emphasising their potential utility within a targeted waitlist intervention.</p><p><strong>Conclusions: </strong>Prehabilitating chronic pain patients towards treatment engagement could circumvent cycles of failed treatment seeking, preventing psychological and physical decline, and reducing healthcare utilisation. Utilising the waitlist to identify psychosocial risk factors (external health locus of control, low self-efficacy and high pain catastrophizing) would identify <i>who</i> requires additional support to prevent increased risk of treatment failure, enhancing personalised care before prescribed treatment is accessed. This review cements the urgent need for pain services to engage proactively with prehabilitation innovation.</p>","PeriodicalId":46585,"journal":{"name":"British Journal of Pain","volume":"18 4","pages":"354-364"},"PeriodicalIF":1.3,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11289902/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141876306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
British Journal of Pain
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1